Clonal Hematopoiesis of Immunological Significance
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jul 23, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Clonal Hematopoiesis of Immunological Significance," is focused on understanding certain immune system diseases and conditions, particularly those linked to a syndrome called Vexas. Researchers want to learn more about how these diseases affect patients and what symptoms they may cause. The study will involve participants from various centers across the country and is designed to gather information over time, making it a unique opportunity to contribute to important medical knowledge.
To be eligible for this study, participants need to be at least 18 years old and have confirmed immune system issues, which can be determined through medical tests or the presence of specific symptoms. The trial is not currently recruiting participants, but when it begins, those who meet the criteria will be able to share their experiences and health information to help researchers better understand these complex conditions. It's important to know that individuals who are in certain protected situations, like those under guardianship or not part of the social security system, will not be able to participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>=18 years old
- • Confirmed dysimmune manifestations: clinical or biological abnormality or systemic disease
- • Presence or absence of myeloid or lymphoid blood disease according to World Health Organization (WHO) classification
- Exclusion Criteria:
- • Persons benefiting from special protection: adults under guardianship and curatorship; people hospitalized without their consent and not protected by law; persons deprived of liberty.
- • Persons not affiliated to the social security system
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Arsene MEKINIAN, MD PhD
Principal Investigator
Service de médecine interne, Hôpital Saint Antoine, APHP, Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported